Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...
Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace ...
As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...
BioAtla is laying off 30% of staff as the biotech searches for partners for some of its conditionally active biologic (CAB) ...
NT219 in combination with EGFR antibody cetuximab (Erbitux) is currently entering a Phase 2 study for head and neck cancer REHOVOT, Israel, March 05, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd ...
The first-line combination of amivantamab-vmjw plus lazertinib extended OS compared with osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer, according to data from the ...
Charles Schwab Investment Management Inc. bought a new position in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX – Free ...
Clinical Trials Arena on MSN6d
First subject enrolled in MUSC Hollings’ Phase II/III trial of HNSCC treatmentHollings Cancer Center, US, has enrolled the first subject in the Phase II/III FORTIFI-NH01 trial of ficerafusp alfa to treat ...
HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCCUpdated data from ongoing Phase 1/1b trial in 1L ...
This presentation will highlight a preclinical dataset that provides insights into the role of inhibiting TGF-β in overcoming acquired KRAS-G12C-inhibitor drug-resistant KRAS-G12C-mutated lung cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback